Related Experiment Video

Updated: Oct 2, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Undertreatment of cardiac risk factors in adolescents with renal failure

U Querfeld1

  • 1Department of Pediatric Nephrology, Humboldt University, Charité University Hospital, Berlin, Germany. uwe.querfeld@charite.de

Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|March 13, 2002
PubMed

Insights

Cardiovascular disease (CVD) is the leading cause of death in adults with end-stage renal disease. Research indicates risk factors contribute to atherosclerosis, but therapeutic intervention effectiveness remains unknown.

Area of Science:

  • Nephrology
  • Cardiology
  • Public Health

Background:

  • Cardiovascular disease (CVD) is the primary cause of mortality in end-stage renal disease (ESRD) patients and post-renal transplant recipients.
  • The excess mortality from CVD is particularly pronounced in younger individuals within these populations.
  • Atherosclerosis, uremic vasculopathy, and uremic cardiomyopathy are implicated, driven by accumulated classical and uremic risk factors.

Purpose of the Study:

  • To investigate the role of classical and uremic risk factors in cardiovascular disease development in chronic kidney disease (CKD) patients.
  • To evaluate the potential impact of therapeutic interventions on modifying these risk factors.

Main Methods:

  • Review of prospective studies examining cardiovascular risk factors in general and CKD populations.
  • Analysis of established classical and uremic risk factors associated with CVD.

Main Results:

  • Prospective studies confirm the significance of both classical and uremic risk factors for CVD in both the general population and those with chronic renal disease.
  • The accumulation of these risk factors is strongly linked to atherosclerosis, uremic vasculopathy, and cardiomyopathy.

Conclusions:

  • While risk factors for CVD in ESRD and post-transplant patients are well-established, their modification through therapeutic interventions requires further investigation.
  • The effectiveness of interventions in reducing CVD morbidity and mortality in these vulnerable populations is currently unknown.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...